SIGA Technologies, Inc.
SIGAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeSIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company carries a $341.4M market cap, placing it firmly in the small-cap category. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Market Cap
$341.4M
Beta
0.85
P/E (TTM)
17.00
P/E (Fwd)
4.53
EPS (TTM)
$0.28
EPS (Fwd)
$1.05
ROE
11.0%
ROA
5.5%
Cash
$145.6M
Total Debt
$601,016
Free CF
$59.4M
52W Change
-20.4%
Annual Financials
Cash vs Debt
With $145.6M in cash and $601K in debt, SIGA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $59.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 11.0% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $110.8M (2022) to $94.6M (2025), a 15% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence SIGA Technologies, Inc.'s trajectory.